

Scientific Symposium 2016

Current Outlook and Future Trend in HIV Treatment

2016 國際學術研討會：愛滋病治療展望與未來趨勢

Aug
Friday / 12

Grand Ballroom I, Grand Hyatt, Taipei 台北君悅飯店凱悅廳1區

Sponsor: United BioPharma, Inc. 聯合生物製藥股份有限公司

Advisor : Centers for Disease Control, Taiwan Ministry of Health and Welfare
衛生福利部疾病管制署

“HIV cure research has the potential to alter the future of this epidemic,” said Nobel Laureate Françoise Barré-Sinoussi. “With 37 million people currently living with HIV worldwide, and another 2 million newly infected each year, an effective approach to curing or achieving sustained remission of HIV infection would be a groundbreaking advance in global health.”

“愛滋病的治癒相關研究具有改變這一傳染病未來的潛力。全球現在約有三千七百萬萬人感染HIV，而每年更有約兩百萬的新增感染案例。全球衛生的突破性進展將會建立在達成HIV感染的治癒或持續緩解這一前題之上” 諾貝爾醫學獎得主弗朗索瓦絲·巴爾-西諾西(Françoise Barré-Sinoussi)

This symposium provides a unique platform to exchange new ideas and approaches dealing with unmet needs in HIV treatment including ultimate functional cure of HIV infection.

本次學術研討會將針對愛滋病治療現況與未來發展趨勢，邀請國內外專家進行分享與交流，包括功能性治癒HIV感染等國際熱門主題。

The key topics and features of this symposium include:

研討會會議核心主題包括：

1. Current and future antiretroviral therapy – effective viral suppression and ART interruption
現在及未來的抗病毒治療趨勢 - 有效抑制病毒及間斷藥物治療
2. Adaptive immunotherapy for HIV with innovative antibody drugs
細胞移植性免疫療法與創新抗體藥物在HIV治療上的應用
3. Strategies for overcoming HIV drug resistance
克服HIV病毒抗藥性之策略
4. HIV persistence, reservoir, latency, and eradication (functional cure)
HIV病毒的持續感染，傳染窩，潛伏性，與清除/功能性治癒

Contact Person: Hayley Chen陳俞姘; hayley.chen@unitedbiopharma.com; 886-3-668-4800 ext 3641

Agenda

Time	Speaker / Topic
09:00 — 09:30	Registration
09:30 — 09:45	Chang Yi Wang王長怡, PhD, Chairperson, UBI group of companies Hsu-Sung Kuo郭旭崧, MD, MPH, PhD, Director-General, Centers for Disease Control, Ministry of Health and Welfare, R.O.C. Welcome and Opening address Daniel R. Kuritzkes, MD

- 09:45 — 10:15 **Progress towards HIV Cure**
- 10:15 — 10:45 Mathias D. Lichtenfeld, MD, PhD
Diversity of the HIV-1 reservoir in CD4 T cell subsets
- 10:45 — 11:15 Jonathan Li, MD
Predictors of HIV rebound after treatment interruption
- 11:15 — 11:45 Flossie Wong-Staal黃以靜, PhD
Treatment with Potential for functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
- 11:45 — 13:00 **Lunch Break**
- 13:00 — 13:30 Wing-Wai Wong王永衛, MD
Viral suppression with UB-421 monotherapy in HIV infected adults
- 13:30 — 14:00 Tae-Wook Chun, PhD
Therapeutic strategies aimed at achieving sustained virologic remission in HIV infection
- 14:00 — 14:30 Hao Wu吳昊, MD
Long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV
- 14:30 — 15:20 Yi-Ming Chen陳宜民, MD, ScD – Moderator
Panel Discussion
- 15:20 — 15:30 Mei-June Liao廖美君, PhD, President, United BioPharma, Inc.
Closing Remarks

Distinguished guest speakers



Daniel R. Kuritzkes, MD

Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women's Hospital

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and is a member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy. He currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group. His research interests focus on antiretroviral therapy, drug resistance and HIV eradication.



Mathias D. Lichterfeld, MD, PhD

Associate Professor of Medicine at Harvard Medical School

Dr. Lichterfeld's research interests focus on understanding mechanisms of natural control of HIV-1 infection in "elite controllers", and on developing clinical strategies that may lead to a long-term drug-free remission of HIV-1 infection in a broader patient population.



Jonathan Li, MD

Assistant Professor of Medicine at Harvard Medical School and Brigham and Women's Hospital

Dr. Li is a translational HIV researcher with an active program focused on HIV persistence, therapeutic vaccines, and minority variants.



Flossie Wong-Staal 黃以靜, PhD

Chair Professor Emeritus, University of California, San Diego; Board member, United Biomedical Inc., Academician, Academia Sinica

Flossie Wong-Staal, is one of the world's authorities on the human immunodeficiency virus (HIV) and amongst the first to clone and genetically map the virus, a major step in proving that HIV is the cause of AIDS. Being a UBI board member, Dr. Wong-Staal has encouraged UBI's translational HIV research team led by Dr. Chang Yi Wang on developing UB-421, a competitive HIV entry inhibitor targeting CD4, as an immunological strategy to reduce HIV-1 persistence, and on evaluating such an intervention in clinical studies.



Wing Wai Wong 王永衛, MD

Attending Physician, Division of Infectious Disease, Taipei Veterans General Hospital, Taiwan 臺北榮民總醫院內科部感染科主治醫師

Wing Wai Wong, as Principal Investigator on several multicenter clinical studies on HIV, has numerous publications regarding the outcome and impact of HIV drug treatment in patients in the Asia-Pacific region.



Tae-Wook Chun, PhD

Chief, HIV Immunovirology Unit, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.

Tae-Wook Chun discovered and characterized latently infected, resting CD4+ T cells in HIV-infected individuals while working in the laboratories of Dr. Antony Fauci at US NIAID, NIH. Currently, as Chief of HIV Immunovirology Unit, he is working towards developing therapeutic strategies aimed at achieving sustained virologic remission in infected individuals without antiretroviral therapy.



Hao Wu 吳昊, MD

Director, Center for Infectious Diseases, Beijing You'an Hospital; Professor, Capital Medical University 首都醫科大學附屬北京佑安醫院感染科教授及主任

Dr. Wu is leading a clinical research team focusing on epidemiological studies of a variety of infectious diseases with special emphasis on public health and clinical issues concerning HIV/AIDS in China.



Yi-Ming (Arthur) Chen 陳宜民, MD, ScD

Legislator of the Legislative Yuan 立法委員; Professor, Center for infectious disease and cancer research, Kaohsiung Medical University 高雄醫學大學傳染病與癌症研究中心主任

Dr. Yi-Ming Chen currently focuses on utilizing Taiwan National Health Insurance Database to analyze risk factors and survival in HIV patients.

請點選下方報名

報名請掃描

Register now



Scientific Symposium 2016

Current Outlook and Future Trend in HIV Treatment

2016 國際學術研討會：愛滋病治療現況與未來趨勢

Grand Ballroom I, Grand Hyatt, Taipei (2, SongShou Road Taipei, Taiwan)

台北君悅飯店凱悅廳1區(台北市信義區松壽路2號)

Aug
Friday / 12

9:30 am
to
3:30 pm

Advisor : Centers for Disease Control, Taiwan Ministry of Health and Welfare
衛生福利部疾病管制署



United BioPharma
聯合生物製藥(股)公司

Photo credit: National Institute of Allergy and Infectious Diseases (NIAID)